Breaking News Instant updates and real-time market news.

AVGR

Avinger

$4.82

0.02 (0.42%)

16:09
10/19/16
10/19
16:09
10/19/16
16:09

Avinger announces expanded FDA indications for Pantheris

Avinger announced that the company has received expanded indications from the FDA recognizing the Pantheris Lumivascular atherectomy system as a technology that can be used for both therapeutic and diagnostic purposes. Pantheris is the first and only image-guided atherectomy device to receive clearance for diagnostic imaging as well as for the simultaneous treatment of PAD. This expanded indication clarifies that, in addition to treatment of PAD, Pantheris may be used by physicians to identify the vessel lumen and wall structures such as intima, internal elastic lamina, media, external elastic lamina and stent struts, as well as vessel morphologies such as calcium, thrombus, fibroatheromas, and necrotic cores.

  • 17

    Nov

AVGR Avinger
$4.82

0.02 (0.42%)

12/29/15
DOTC
12/29/15
DOWNGRADE
DOTC
Neutral
Avinger downgraded to Neutral from Buy at Dougherty
Dougherty analyst Charley Jones downgraded Avinger to Neutral citing balanced near-term risk/reward.
07/07/16
ADAM
07/07/16
NO CHANGE
ADAM
Buy
Canaccord calls Spectranetics, Avinger buys after reimbursement announcement
Canaccord analyst Jason Mills reiterated the firm's Buy ratings on Spectranetics (SPNC ) and Avinger (AVGR) after CMS announced proposed 2017 policy and payment changes to the Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System, noting that the proposal does not include any material changes to outpatient hospital-based peripheral atherectomy payments for next year. The proposed rule for the Physician Fee Schedule will be "the final piece of the outpatient reimbursement puzzle," the analyst tells investors.
07/13/16
ADAM
07/13/16
NO CHANGE
Target $12
ADAM
Buy
Avinger price target lowered to $12 from $20 at Canaccord
Canaccord lowered its price target on Avinger to $12 from $20 after Q2 earnings and a guidance reduction the firm calls disappointing. The firm is keeping its Buy rating on Avinger shares, based on its cash position and the company's ability to drive product development, clinical evidence, and sales force expansion.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.